Scopus BioPharma Inc.
Other OTCTotal Valuation
Scopus BioPharma Inc. carries a market capitalization of 21,042.00, placing it among publicly traded companies globally.
| Market Cap | 21,042.00 |
| Enterprise Value | N/A |
Share Statistics
Scopus BioPharma Inc. currently has 42.08M shares outstanding.
| Shares Outstanding | 42.08M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.03 |
| P/TBV Ratio | -0.16 |
| P/FCF Ratio | -0.54 |
| P/OCF Ratio | -0.54 |
Financial Position
Scopus BioPharma Inc. maintains a current ratio of 0.05, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.05 |
| Quick Ratio | 0.03 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -801.26 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Scopus BioPharma Inc.'s stock has gained approximately 66.66666% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.
| Beta (5Y) | N/A |
| 52-Week Price Change | 66.66666% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -9.34M, while operating income came in at -9.34M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -9.34M |
| Pretax Income | -9.34M |
| Net Income | -8.70M |
| EBITDA | -9.34M |
| EBIT | -9.34M |
| Earnings Per Share (EPS) | -0.31 |
Balance Sheet
Total book value stands at -58.09M, with working capital of -10.51M providing operational flexibility.
| Cash & Cash Equivalents | 362,097.00 |
| Total Debt | N/A |
| Net Debt | -362,097.00 |
| Equity (Book Value) | -58.09M |
| Book Value Per Share | -1.91 |
| Working Capital | -10.51M |
Cash Flow
Scopus BioPharma Inc. produced -3.04M in operating cash flow over the past twelve months.
| Operating Cash Flow | -3.04M |
| Capital Expenditures | N/A |
| Free Cash Flow | -3.04M |
| FCF Per Share | -0.10 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -135.02 |
| FCF Yield | -185.33 |
Scores
Scopus BioPharma Inc. posts an Altman Z-Score of -250.78, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -250.78 |